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ABSTRACT 
Background and Objectives: Typhoid is a major health problem faced by the developing countries like Pakistan. More than 
20 million cases are reported annually worldwide. Currently fluoroquinolones are the drugs of choice to treat typhoid fever. 
In vivo resistance to fluoroquinolones leading to therapeutic failure is developing rapidly and is becoming a major concern 
for the clinicians. The objective of this study was to determine the sensitivity pattern of Nalidixic acid over the last four 
years
Material and Methods: A descriptive cross sectional study was carried out at the Microbiology Department of the Army 
Medical College, National University of Sciences and Technology, Rawalpindi from January 2006 to December 2009. 
All the isolates were dealt with standard microbiological procedures. The antimicrobial sensitivity of Nalidixic acid and 
Ciprofloxacin was determined using Kirby-Bauer disc diffusion method as per the guidelines of Clinical and Laboratory 
Standard Institute (CLSI).
Results: Out of 240 isolates, 111 were Salmonella typhi and 129 were Salmonella paratyphi A. The resistance of the 
typhoidal Salmonella to Nalidixic acid has reached significant levels and it seems only a matter of time when hundred percent 
resistance will be encountered. All isolates were sensitive to Ciprofloxacin on disc diffusion method.
Conclusion: Resistance to Nalidixic acid predicting therapeutic failure with fluoroquinolones is on a steady rise.
Keywords: Nalidixic acid resistance, Therapeutic failure, typhoid, typhoidal Salmonella
INTRODUCTION
Typhoid  has  been  a  menace  to  humanity  for 
centuries. It caused the fall of Athens in 430 B.C., 
ending the Golden Age of Pericles (1). It continues to 
plague the developing world even in the 21st century. 
The  morbidity  of  typhoid  fever  is  highest  in Asia 
with 93% of global episodes occurring in this region. 
Southeast Asia  has  an  estimated  incidence  of  110 
cases/100,000 population, which is the third highest 
incidence rate for any region (2).
In  Asia,  Pakistan  has  the  highest  incidence  of 
Salmonella typhi (S. Typhi) and Salmonella paratyphi 
A ( S.  Paratyphi  A)  (3).  In  the  1970’s,  antibiotic 
resistance  against  conventional  antityphoid  drugs 
emerged for the first time. By the mid 1990’s multidrug 
resistant  strains,  i.e.  those  having  simultaneous 
resistance to the three conventional antityphoid drugs 
(chloramphenicol, trimethoprim-sulfamethoxazole 
and ampicillin), became rampant all over the world. 
Fluoroquinolones then became the treatment of choice 
for typhoid fever (4). Widespread, injudicious use of 
these drugs, has led to the emergence of resistance.
So far, in-vitro fluoroquinolone resistance has not 
been  reported  on  a  widespread  scale  in  Pakistan. 
Therapeutic failure with fluoroquinolones, however, 
is being reported from various parts of Pakistan with 
increasing frequency (5). In the laboratory, using the 
routine disc diffusion tests, isolates with decreased in 
vivo susceptibility to ciprofloxacin appear susceptible 
(6). 
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Nalidixic acid is a naphthyridone but is considered 
to be the first of the synthetic quinolone antibiotics. 
It has structural similarity with the newer generation 
quinolones. A single point mutation in the quinolone 
resistance-determining region (QRDR) of the gene gyrA 
in  Salmonella  leads  to  resistance  against  nalidixic 
acid  as  well  as  decreased  in  vivo  ciprofloxacin 
susceptibility (7). Thus, resistance to nalidixic acid 
is  used  as  an  indicator  of  decreased susceptibility 
to the fluoroquinolones (8). The aim of this study was 
to determine the current trend in the nalidixic acid 
sensitivity in Typhoidal Salmonellae.
MATERIAlS AND METHODS
A descriptive cross sectional study carried out at the 
Microbiology  Department, Army  Medical  College, 
National  University  of  Sciences  and  Technology 
(NUST), Rawalpindi, from January 2006 to December 
2009. 
Blood  culture  samples  were  received  from  the 
wards  of  an  1,100  bed  tertiary  care  hospital,  the 
Military Hospital (MH) of Rawalpindi. The samples 
were collected aseptically using a disposable syringe. 
The top of the culture bottle was cleaned with iodine 
immediately  before  addition  of  blood.  Five  ml  of 
venous blood drawn from adults was added to fifty 
ml of sterile Brain Heart Infusion (BHI) (Merck). For 
children, the ratio used was 3 ml of blood in 30 ml 
BHI (Merck). 
Subcultures were made on Blood and MacConkey’s 
agar (Oxoid, Basingstoke, UK) at 24 hr, 48 hr, and 
5th and 7th day. Cultures that showed no growth till 
the  seventh  day  were  reported  as  negative.  The 
species were identified on the basis of morphology 
and  standard  biochemical  tests  using  API  20E 
(Biomerieux, France) and the serovars were confirmed 
as S. Typhi and S. Paratyphi A by serological tests 
using standard anti-sera (Bio-Rad) using polyvalent 
A-S, O9 for S.Typhi and O2 for S. Paratyphi A.                                                                                                                                                                                                                         
Antimicrobial susceptibility was tested for nalidixic 
acid and ciprofloxacin using discs of 30 µg and 5 µg 
respectively (Britania, Argentina) on Mueller-Hinton 
agar (Britania) by Kirby-Bauer disc diffusion method 
as per the Clinical and Laboratory Standards Institute 
(CLSI)  guidelines ( 9).  The  plates  were  incubated 
at 37ºC for 24 hours. The control strain used was 
Escherichia coli ATCC 25922. The data was analyzed 
using SPSS version 17.0. 
RESUlTS
A total of 240 typhoidal Salmonellae were isolated 
during the study period. Out of these, 111 were S. Typhi 
and 129 were of S. Paratyphi A. There was an increase 
in the isolation rate of S. Paratyphi A compared to S. 
Typhi in 2007-2009. (Fig. 1) The subjects age ranged 
from one to ninety years old (mean = 33.7 years). The 
male to female ratio was 17.1:1. 
All 240 isolates were sensitive in-vitro to ciprofloxa-
cin throughout these four years. The sensitivity was 
checked  using  5  µg  Ciprofloxacin  discs  (Britania, 
Argentina)  on  Mueller–Hinton  agar  (Britania)  by 
Kirby-Bauer disc diffusion method. 
The resistance to nalidixic acid in S. Paratyphi A 
increased with each subsequent year. In 2006, it was 
69%. It increased slightly to 72% in 2007, became 
77%  in  2008  and  in  2009  more  than  93%  of  the 
isolates of S. Paratyphi A were resistant to nalidixic 
acid. (Fig. 2)
A similar pattern was observed in S. Typhi, with 
66% of isolates being resistant to nalidixic acid in 
2006. This increased to 75 and 79% in 2007 and 2008 
respectively. In 2009, all the isolates were resistant to 
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nalidixic acid. (Fig. 3)
A  comparison  of  the  resistance  pattern  of  both 
serovars revealed that the resistance to nalidixic acid 
is rising equally in both. (Fig. 4)
DISCUSSION
Typhoid continues to be a major health problem 
in Pakistan. Its treatment still remains a challenge 
due to the rapid emergence of antibiotic resistance in 
the causative strains. In an attempt to determine the 
current resistance pattern of the typhoidal Salmonellae 
in our region, we compared the sensitivity trends of 
Salmonella enterica subspecies typhi and paratyphi A 
isolated between 2006 and 2009.
In our study, several interesting trends were observ-
ed. A decrease in the isolation rate of Salmonella over 
the past 4 years was observed (from 81 in 2006 to 
41 in 2009). This concurs with the study conducted 
at the Armed Forces Institute of Pathology in which 
the isolation rate of typhoidal Salmonellae decreased 
significantly from 147 in 1996 to 49 in 2003 (10). 
This however, doesn’t suggest that the incidence of 
typhoid fever has gone down, as the various factors 
responsible for the endemicity of typhoid in Pakistan 
have not changed. 
Another trend seen was the increase in the relative 
proportion of S. Paratyphi A isolates compared to S. 
Typhi (53.04% S. Paratyphi A and 47.39% S. Typhi). 
The incidence of enteric fever caused by S. Paratyphi 
A has been increasing. This is similar to the reports 
from a regional study by Thankhiwale et al . (11).
In a study conducted in the United States by Michael 
F Lynch et al., 38 percent resistance to nalidixic acid 
was reported in isolates from the year 1999 to 2006 
(12). In India, S. Paratyphi A isolation rates in enteric 
fever cases were reported to be 26, 27 and 52% in 
2003, 2004, and 2005 respectively (13). Chandel et 
al.  attribute  this  dramatic  increase  in  incidence  of 
enteric fever by S. Paratyphi A to the widespread 
use of vaccines and quinolones against S. Typhi in 
the past decade (14). In our study, the incidence of S. 
Paratyphi A isolates was found to be 48, 49, 53 and 
71% in 2006, 2007, 2008 and 2009 respectively.
Nalidixic acid screening has been used to detect 
and predict decreased fluoroquinolone susceptibility 
in  typhoidal  Salmonella.  Identification of  nalidixic 
acid resistance by the disk diffusion method provides 
a sensitivity of 100% and a specificity of 87.3% (8).
Nalidixic acid resistance was found to be increasing 
in both S. Typhi and S. Paratyphi A during the last 
four years. All S. Typhi have developed resistance to 
nalidixic acid whereas S. Paratyphi A also seems to 
be catching up fast. This is in sharp contrast to the 
study carried out in 2001-2002 in the same setting, 
in which only 4% of the isolates were found to be 
resistant to nalidixic acid (15).
Despite  the  increasing  resistance  to  nalidixic 
acid, all 240 isolates were found to be sensitive to 
ciprofloxacin in-vitro. This is in accordance with a 
regional study by Asna, et al. in 2003 that found that 
the isolates with decreased in vivo susceptibility to 
ciprofloxacin  appear susceptible  with  routine  disc 
diffusion tests (6).
The first case of fluoroquinolone treatment failure 
in typhoid Salmonellae was reported in Pakistan in 
1993 (16). Since then the incidence of such cases 
has  been  increasing.  Inability  to  identify  reduced 
susceptibility to fluoroquinolones by the standard disk 
diffusion techniques further compounds the problem. 
A reappraisal and revision of the current guidelines 
for detection of this resistance is necessary. 
In  conclusion,  there  is  a  definite  shift  in  the 
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distribution  as  well  as  antimicrobial  susceptibility 
of typhoidal Salmonellae in Pakistan. The resistance 
to nalidixic acid is on a steady rise in both serovars. 
This foretells a rise in therapeutic failure with the 
fluoroquinolones. It is imperative that these drugs be 
used judiciously to limit the spread of resistance and 
new, reliable treatment options must be sought before 
untreatable typhoid fever becomes a major problem.
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